Gilead Sciences, Inc.

NasdaqGS:GILD 株式レポート

時価総額：US$163.1b

Gilead Sciences 配当と自社株買い

配当金 基準チェック /56

Gilead Sciences配当を支払う会社であり、現在の利回りは2.46%で、収益によって十分にカバーされています。

主要情報

2.5%

配当利回り

0.8%

バイバック利回り

総株主利回り3.2%
将来の配当利回り2.2%
配当成長7.3%
次回配当支払日n/a
配当落ち日n/a
一株当たり配当金n/a
配当性向43%

最近の配当と自社株買いの更新

Recent updates

ナラティブ更新 • May 01

GILD: Future Returns Will Hinge On Executing Oncology And ADC Acquisitions

Analysts have raised the Gilead Sciences fair value estimate by about $2 to $128.42 per share, supported by refreshed models that reflect updated revenue growth, profitability, and future P/E assumptions following a wave of higher Street price targets. Analyst Commentary Street research on Gilead has tilted constructive in recent weeks, with several firms lifting price targets and at least one new Buy rating added.
Seeking Alpha • Apr 20

Gilead Sciences: Why I'm Tempted To Sell Ahead Of Q1 Earnings - But Won't

Summary Gilead Sciences, Inc. remains heavily reliant on its dominant HIV division, which drives recent share price growth and provides stability through 2036 patent protection. Despite a recent $11bn M&A spree targeting oncology and immunology, GILD faces skepticism due to a poor track record and lack of near-term revenue from new acquisitions. I expect Q1 earnings to be somewhat underwhelming, with sluggish growth and minor IPR&D charges, but GILD trades at a below-average forward P/E of ~16x versus peers. I continue to hold GILD for its robust HIV franchise and >2% dividend yield, while awaiting evidence that management can successfully execute on oncology ambitions. Read the full article on Seeking Alpha
ナラティブ更新 • Apr 17

GILD: Oncology Deals And HIV Franchise Will Support Future Earnings

Analysts have raised the price target for Gilead Sciences to $180, citing recent upward revisions across Wall Street that reflect updated views on revenue growth, profitability and oncology deal activity. The core fair value estimate in this framework also remains at $180.
ナラティブ更新 • Apr 03

GILD: HIV And PrEP Franchise Will Support Future Earnings And Margin Strength

Analysts have lifted the fair value estimate for Gilead Sciences to $180 from $159, citing higher modeled revenue growth, a slightly lower discount rate, and support from a wave of recent price target raises and positive initiation commentary on the company’s positioning and operating margins. Analyst Commentary Street research around Gilead Sciences has been active, with several bullish analysts updating their views and price targets in recent weeks.
ナラティブ更新 • Mar 20

GILD: HIV Franchise And Oncology Expansion Will Shape Bullish Long Term Outlook

The analyst fair value estimate for Gilead Sciences has moved from $132.57 to $157.43, with analysts pointing to stronger modeled revenue growth, slightly higher long term profit margins, and a higher future P/E multiple supported by recent price target hikes and positive views on the company's positioning in large cap biotech. Analyst Commentary Recent Street research on Gilead Sciences reflects a mix of optimism around growth drivers and caution around valuation and competitive risks.
ナラティブ更新 • Mar 05

GILD: Rich HIV Outlook Will Depend On Delivering High-Risk Oncology Acquisitions

Analysts have lifted their Gilead Sciences fair value estimate from $122.64 to $126.09 as they update models to reflect revised revenue growth and profit margin assumptions, along with a slightly higher discount rate and a modestly lower future P/E multiple, following a wave of higher Street price targets in recent weeks. Analyst Commentary Recent Street research around Gilead Sciences shows a mix of optimism and restraint.
ナラティブ更新 • Feb 19

GILD: Elevated Future Expectations Will Hinge On Execution In Oncology

Gilead Sciences' updated analyst price target has moved sharply higher to $122.64 from $91.83, as analysts broadly lift their targets into the $140 to $170 range, citing steadier HIV franchise expectations, contributions from recent launches, and adjusted assumptions for expenses and oncology assets. Analyst Commentary Recent Street research shows a clear tilt toward higher valuation frameworks for Gilead Sciences, with several firms taking their targets into a broad US$140 to US$170 range.
ナラティブ更新 • Feb 05

GILD: Extended HIV And PrEP Strength Will Support Steady Long-Term Earnings Power

Narrative Update: Gilead Sciences Analyst Price Target Shift Analysts have lifted their price targets on Gilead Sciences by as much as US$20, pointing to updated HIV franchise expectations, revised oncology and PrEP assumptions, and refreshed valuation approaches, even as some models incorporate higher IPR&D expenses and adjusted sales forecasts. Analyst Commentary Recent Street research around Gilead centers on two big themes in the models: the durability of the HIV franchise and the ramp in newer areas like PrEP and oncology, with several bullish analysts lifting price targets and reaffirming positive ratings.
ナラティブ更新 • Jan 22

GILD: Extended HIV Franchise Strength Will Support Stronger Long-Term Earnings Power

Analysts have nudged their fair value estimate for Gilead Sciences up to $159 from $153, citing refreshed models that reflect updated HIV franchise expectations, oncology pipeline inputs, and evolving competitive readthroughs from peers in hepatitis and cell therapy. Analyst Commentary Recent Street research around Gilead Sciences has leaned constructive, with several bullish analysts refining their models and resetting price targets while pointing to HIV, oncology, and select liver and autoimmune assets as the key drivers they are watching.
ナラティブ更新 • Jan 07

GILD: HIV PrEP Strength And Oncology Mixed Results Will Shape Outlook

Analysts have nudged their price targets on Gilead Sciences higher, generally toward the US$140 to US$145 range. They cite expectations for stronger HIV PrEP contributions from Yeztugo, a healthier outlook for the broader HIV portfolio including Biktarvy, and ongoing support from oncology and newer launches such as Livdelzi.
ナラティブ更新 • Dec 20

GILD: Extended HIV Exclusivity Will Support Stronger Long-Term Earnings Power

Analysts have raised their fair value estimate for Gilead Sciences to $153 from $140, citing extended Biktarvy exclusivity, a stronger long term HIV growth outlook supported by Yeztugo and PrEP, and increasing conviction in oncology and broader large cap biopharma innovation potential. Analyst Commentary Bullish analysts continue to highlight Gilead as a core large cap biopharma holding, pointing to a healthier long term growth profile in HIV and a strengthening contribution from oncology.
ナラティブ更新 • Dec 06

GILD: Extended HIV Franchise Will Offset Oncology And Policy Uncertainty Ahead

Analysts have nudged their blended price target for Gilead Sciences slightly lower by about $0.20 to the low-$130s, reflecting modestly higher discount rates and more conservative HIV and oncology growth and margin assumptions, even as they highlight extended Biktarvy exclusivity, encouraging Yeztugo uptake, and anito cel driven oncology optionality as key long term value drivers. Analyst Commentary Bullish analysts largely frame the recent price target tweaks as fine tuning within an increasingly constructive long term view, pointing to extended HIV cash flows, a strengthening PrEP opportunity, and optionality in oncology despite early stage competitive readouts.
ナラティブ更新 • Nov 22

GILD: Extended Exclusivity And PrEP Opportunities Will Balance Ongoing Oncology And Policy Pressures

Analysts have modestly raised their price target for Gilead Sciences to $130.83 per share from $129.51. They cite the extended exclusivity period for Biktarvy and improved growth prospects in the HIV market as key drivers for the upward revision.
ナラティブ更新 • Nov 08

GILD: HIV Business Strength And Patent Extension Will Balance Oncology Risks Ahead

Gilead Sciences' price target has been raised by analysts from $127 to $145. This reflects confidence in stable HIV business trends and improved execution, which offsets ongoing oncology and cell therapy challenges.
ナラティブ更新 • Oct 25

Patent Extension And Policy Decisions Will Drive Access To Advanced Therapies

Gilead Sciences' analyst price target has increased from $126 to $127 per share. Analysts point to continued strong uptake of the Yeztugo launch in HIV and the recent Biktarvy patent extension as supporting factors, despite some pipeline setbacks.
ナラティブ更新 • Oct 10

Global Healthcare Trends Will Expand Access To Advanced Therapies

Gilead Sciences saw its analyst price target increase from $124.91 to $126.31. Analysts cited improved sales forecasts for key HIV treatments and enhanced revenue growth expectations as the primary drivers of the upward revision.
ナラティブ更新 • Sep 04

Global Healthcare Trends Will Expand Access To Advanced Therapies

Analysts remain constructive on Gilead Sciences, citing strong HIV franchise performance, positive FDA developments, and favorable regulatory tailwinds offsetting minor pipeline setbacks, resulting in an unchanged consensus price target of $124.37. Analyst Commentary Yeztugo’s FDA approval and clean label, strong clinical data, and convenient twice-yearly dosing are seen as key drivers for Gilead’s HIV franchise growth, with analysts generally positive on long-term adoption despite initial ramp expectations being slow and some cannibalization of Descovy anticipated.
分析記事 • Jul 27

Does Gilead Sciences (NASDAQ:GILD) Have A Healthy Balance Sheet?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
分析記事 • May 15

Statutory Profit Doesn't Reflect How Good Gilead Sciences' (NASDAQ:GILD) Earnings Are

Even though Gilead Sciences, Inc.'s ( NASDAQ:GILD ) recent earnings release was robust, the market didn't seem to...
Seeking Alpha • Apr 25

Gilead Sciences Q1 Earnings Review: HIV Division Masks Underperformance

Summary Gilead Sciences' Q1 2025 earnings report shows a slight decline in product sales, primarily due to lower Veklury sales and oncology inventory issues. The HIV division remains Gilead's strongest performer, with Biktarvi leading the charge, while oncology investments have yet to yield significant returns. Key upcoming milestones include the FDA decision on lenacapavir, a potential blockbuster HIV therapy, and various oncology and cell therapy data readouts. Despite recent share price growth, I am downgrading GILD stock to "Hold" due to concerns over oncology and cell therapy prospects and limited upside potential. Read the full article on Seeking Alpha
新しいナラティブ • Apr 08

New HIV, Livdelzi And CAR T Options Will Expand Reach

Gilead's innovation in HIV and oncology treatments supports revenue growth and market expansion in these therapeutic areas.
Seeking Alpha • Mar 16

Gilead: Growth Constraints Lead To Rating Downgrade Following 50% Rally

Summary Gilead's HIV portfolio remains dominant but faces Medicare Part D pricing pressure, limiting future growth potential. New launches like Livdelzi provide growth opportunities but are unlikely to overcome the flat HIV segment forecast. DCF modeling shows Gilead is priced for 0% growth, which aligns with near-term revenue expectations. Heavy reliance on HIV franchise (72% of revenue) creates vulnerability despite diversification efforts in oncology. Following a 57% rally since June, Gilead now trades at fair value relative to its modest growth outlook, meriting a rating downgrade to "hold" and "market perform." Read the full article on Seeking Alpha

決済の安定と成長

配当データの取得

安定した配当: GILDの1株当たり配当金は過去10年間安定しています。

増加する配当: GILDの配当金は過去10年間にわたって増加しています。

配当利回り対市場

Gilead Sciences 配当利回り対市場
GILD 配当利回りは市場と比べてどうか？
セグメント配当利回り
会社 (GILD)2.5%
市場下位25% (US)1.4%
市場トップ25% (US)4.2%
業界平均 (Biotechs)2.5%
アナリスト予想 (GILD) (最長3年)2.2%

注目すべき配当: GILDの配当金 ( 2.46% ) はUS市場の配当金支払者の下位 25% ( 1.42% ) よりも高くなっています。

高配当: GILDの配当金 ( 2.46% ) はUS市場の配当金支払者の上位 25% ( 4.24% ) と比較すると低いです。

株主への利益配当

収益カバレッジ: GILDの 配当性向 ( 43% ) はかなり低いため、配当金の支払いは利益によって十分にカバーされます。

株主配当金

キャッシュフローカバレッジ: GILDの 現金配当性向 ( 39.8% ) は比較的低く、配当金の支払いはキャッシュフローによって十分にカバーされています。

高配当企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/11 12:57
終値2026/05/11 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Gilead Sciences, Inc. 20 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。66

アナリスト機関
David ToungArgus Research Company
Brian SkorneyBaird
James BirchenoughBarclays